WALTHAM, Mass. - Jan. 22, 2021 - Nova Biomedical announces the addition of a Sample Retain Collector (SRC) for BioProfile FLEX2 cell culture analyzer. The FLEX2 automated cell culture analyzer measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability. A single FLEX2 analyzer with SRC and the previously introduced Online Sampler (OLS) module provides automated sampling and analysis of these key cell culture tests from as many as 10 bioreactors. This FLEX2 automation package saves hours of time versus manual sampling, analysis, sample storage, and after-hours cell culture monitoring.

The SRC automatically collects cell culture samples from the FLEX2 Online Sampler and stores them in a refrigerated environment to fulfill regulatory requirements for long-term sample retains, as well as enabling further offline testing. The SRC allows user-selectable retained sample volumes from 200uL to 50 mL at a storage temperature of 4˚C. In combination with the FLEX2 and OLS, samples from up to 10 bioreactors can be analyzed, and stored by the SRC in as fast as one hour.

Matt McRae, Nova Biotechnology Product Line Manager says "We have partnered with the industry leader in liquid handling systems, Teledyne Cetac, to market this system, configured specifically to work with the FLEX2. The Sample Retain Collection System completes the full automation package for the FLEX2, offering the truly automated sampling, analysis, sample storage and feedback control of all measured parameters that our customers need. It also enables safe storage of retains and/or later analysis of other key cell culture attributes that today's laboratories require."

About Nova Biomedical

Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood point-of-care and critical care analyzers, as well as the most advanced instruments for cell culture monitoring in the biotechnology market. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova's biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova's biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for a broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, and Switzerland.

www.novabiomedical.com

Contact
Matt McRae